(May 14, 2019) We’re excited to announce that Dr. Mary-Claire King, who identified the germline BRCA1 mutation associated with hereditary breast and ovarian cancer, will be a keynote speaker at OCRA’s Ovarian Cancer National Conference! Dr. King is a geneticist and professor at the University of Washington. Her work has helped change the way we … Continued
(May 14, 2019) OCRA received the President’s Award at the first Cancer Community (C2) Awards, created to recognize individuals and organizations who have created positive change in cancer care. The awards – a partnership between AstraZeneca and Scientific American Custom Media – included nominations submitted by organizations from across the cancer ecosystem and participation from … Continued
(April 3, 2019) We have one week to let the Senate know that we need more funding for ovarian cancer research! Thanks to your efforts, a record 158 U.S. House members signed a Dear Colleague letter calling for more funding for the Ovarian Cancer Research Program (OCRP) at the Department of Defense. Now we need … Continued
(April 1, 2019) 156 House Members have joined Reps. DeLauro and Duffy in a call for increased ovarian cancer research funding. Reps. Rosa DeLauro (D-CT) and Sean Duffy (R-WI) – co-chairs of the Congressional Ovarian Cancer Caucus – today delivered a “Dear Colleague” letter to the House Defense Appropriations Subcommittee requesting a $15 million increase in … Continued
(March 20, 2019) The Ovarian Cancer Dream Team, funded in part by OCRA, recently completed a Phase 1b Trial, which combined a PARP inhibitor with an HRR (homologous recombination repair) pathway inhibitor, such as PI3K, in order to increase the efficacy of PARP inhibitors in breast and epithelial ovarian cancers. Phase 1 trials are used … Continued
(March 20, 2019) Earlier this month, OCRA united advocates from across the country for Spring Advocacy Day on Capitol Hill. Together, this passionate group of survivors, caregivers and supporters used their collective voice to advocate for increased funding for ovarian cancer research and education. Learn more about our asks for Ovarian Cancer Research Program (OCRP) … Continued
(March 19, 2019) Congress is considering a $15 million increase for OCRP funding. Urge YOUR Representative to sign the letter to help push this funding through. Deadline is March 25th! Tell Congress to Increase OCRP Funding The Ovarian Cancer Research Program (OCRP) is a cutting-edge program housed within the Department of Defense and despite a … Continued
(March 15, 2019) Cell Reports recently published a study about a drug that, given in combination with chemotherapy, could greatly increase survival rates of ovarian cancer patients. Researchers, including OCRA grantees Illana Chefetz, PhD and Ronald Buckanovich, MD, PhD, identified a new drug, 673A, that finds and destroys stem-like ovarian cancer cells. Stem-like cells are … Continued
(March 12, 2019) “The President’s proposed FY2020 budget released by the White House on Monday seeks to cut medical research funding at the National Cancer Institute (NCI) by 15 percent – almost $900 million dollars compared to FY2019 funding. The budget also slashes the Centers for Disease Control’s (CDC) Chronic Disease Program by almost 20 … Continued
(March 1, 2019) OCRA mourns the loss of our beloved board member and friend, Lori Newcomb. We are profoundly grateful for her vision and dedication in creating Newk’s Cares along with her loving husband, Chris, to support ovarian cancer research through their family business, Newk’s Eatery. Her unwavering and selfless commitment to help other women … Continued
(February 26, 2019) Ovarian Cancer Research Alliance is pleased to announce Beth Y. Karlan, M.D as our new chair of OCRA’s Scientific Advisory Committee. Our Scientific Advisory Committee is comprised of 24 illustrious and respected leaders in research on treating women with ovarian cancer. Dr. Karlan is Professor and Vice Chair of Women’s Health Research … Continued
OCRA is pleased to announce we have earned our NINTH consecutive 4-star rating from Charity Navigator, America’s largest independent charity evaluator. This is the highest rating awarded by Charity Navigator, and demonstrates our steady commitment to responsible fiscal management, organizational transparency, and accountability, as we continue to strive toward cures for ovarian cancer. A 4-star … Continued
Get email updates about research news, action alerts, and ways to join the fight.
